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The/?-amyloid protein @-AP) derived from a&amyloid protein precursor (APP) is a hallmark of Alzheimcr’s disease. The abundant generation 
oT&AP suggests the abnormal promsing of’ APP. but the molecular mechanism remains unclear. The main APP-processing enzyme WRS purified 
from the ral brain and identi!ied to be a macropain-like multicatalytic proleinasc. The purified enzyme clcavcd the Gln’5-Lys’n bond OTB-AP, but 
altered to cleuve at the N-terminus of&AP to rcleasc the cxtracellLdar domain ofp-AP in the presence of Ca”. These findings suggest that the 
functional change in this multicatalytic protcinasc may result in abnormal processing of APP. 
P-Amyloid protein prcsursor; Muhicatalylic protcinasc; Macropain: Ral brain; Calcium ion 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Alzheimer’s disease (AD) is pathologically character- 
ized by extracellular deposits of @amyloid protein (/I- 
AP) in senile plaques and cerebral vessels [l]. /3-AP is 
a small peptide fragment of 39 to 42 amino acids derived 
from a larger amyloid protein precursor (APP) [24]. 
There are at least three different isoforms of APP with 
695,751 and 770 amino acids, generated by alternative 
splicing of mRNA [4-71. P-AP is encoded as an internal 
peptide at position 597-638 of APP695 [4]. The normal 
processing occurs within the &AP sequence preventing 
the generation of /3-AP [8,9]. Therefore, the abundant 
generation of,&AP in the Alzheimer brain suggests the 
abnormal processing of APP. but the molecular mecha- 
nisms of normal and abnormal processing of APP re- 
main unclear. 
To investigate the APP-processing enzyme and the 
@-AP-releasing enzyme in the rat brain, we used peptide 
AP33 (SEVKMDAEFGHDSGFEVRHQKLVFFAE- 
DVGSNK), synthesised according to the sequence (res- 
idues 592-624) of rat APP695 [lo]. The peptide consists 
of the extracellular domain of p-AP, i.e. from Asp’ to 
Lys?*, and five amino acids upstream from the N termi- 
nus offi-AP, i.e. Serm5 to Met-‘. The enzyme activity was 
determined by the AP33 fragmentation assay. 
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2.1, Assq Jut- A PP-prosesdig erqwe urfd B-A P-r&using en:_strte 
Peptidc Al’33 (SEVKMDAEFGHDSGFEVRHQKLVFFAEDV- 
GSNK) was synthesized by the solid-phase method using a Beckman 
990 peptidc synthesizer. The peptide chain was elongated on a chlo- 
romcthylated polystyrene resin using No-Boc derivatives ofappropri- 
ate amino acids, The peptidc resin was treated with anhydrous hydro- 
gen fluoride to cleave the peptide from the resin and to remove all 
prolecting groups. The crude pcptidc was purified by reverse-phase 
HPLC on a YMC ODS column (30 x 250 mm). AP33 (I ~8) was 
incubated with the sample in 40 ~1 of aariay buffer (SO mM HEPES, 
pH 7.0) for I h at 37°C. The enzyme reaction was terminated by the 
addition of 4Oyl of 2% trifluoroacelic acid (TFA). The reaction mix- 
ture (40 yl) was chromatographed by reverse-phase HPLC on a Bio- 
Rad RP-304 column (4.6 x 250 mm) using burer A (0.1% TFA) and 
bufl’er B (0.07% TFA-95% acetonitrilc). The chromatographic run 
was pcrformcd at a Row rate of 1 ml/min using a 20-ml inear gradient 
from 0% to 40% buffer B and a Z-ml linear gradient o iOO% buffer 
B. One unit of APP-processing activity was defined as the amounl of 
cnzymc that catalyses AP33 as substrate to form one pmol of the 
peptidc fragment corresponding to residues 16-28 of/l-AP in I h at 
37°C. 
bruin 
About 70 frozen rat brains were homogenized in 60 ml of 50 mM 
HEPES. 1 mM EDTA, pH 7.5. Insoluble material was removed by 
centrifugation (40,ORD rpm x 30 min), The supematant (35 ml) was 
chromatographed at a flow rale of 300 ml/h on two Sephadcx G-150 
columns (11.2 x 20 cm) connected in series equilibrated with 20 mM 
HEPES. pH 7.0. Fractions (45 ml) were collected. AP33 (50 pg) was 
incubated for 3 h at 37°C with 0.5 ml of high-molecular-mass fraction 
(,V,rlOO kDa) in the presence of0.3 mM CaC12. The resulting Trag 
mcnts were purified by reverse-phase HPLC on an RP-304 column 
and analyixl for the N.tcrminal amino acid sequence on a protein 
sequencer [Applied Biosystems, model 477A) and a phcnylthiohydan- 
toin (PTH) amino acid analyzer (model 120Aj. while lhc amino acid 
compositions were determined on an amino acid analyzer (Hitachi, 
model 835). 
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2.3. Pur#crriiorf md cAurirctcri:rtriott 0J’ .4 PP-pr0cc’SSitlg tW:.WW 
The enzyme-rich fractions (Nos. 36-41) of Scphadcx G-l 50 chrom- 
atography were dialyzed against 8 liters of 20 mM Tris-HCI. pH 7.5 
(bulk C). The dialyzed enzyme solution wns applied onlo a ben- 
zamidinc-Sepharosc 6Bcolumn (I .6 x 25 cm) and clutcd at a ROW rate 
of 2.0 mllmin with a gradient of O-l M NaCl in 240 ml of buffer C. 
Fractions (6 ml) were collected. The active fractions (Nos, 19-26) were 
diluted twofold with bull-cr C. The enzyme solution was applied onto 
a TSK DEAE-5PW column (7.5 x 70 mm) and eked at a llow rate 
of I .O ml/min with a gradient of O-l M NaCl in 60 ml of buffer C. The 
active fraction was rcchromatoyrophed on the same column. Frac- 
tions (0.5 ml) were collected. Thr active fractions (Nos. 66-68) were 
pooled and stored at -70°C. The purified enzyme was analyzed on a 
4-3046 polyacrylamide Sradient gel without SDS and on a IO-20% 
polyacrylamide gel with SDS according to the method of Laemmli 
[l I]. The gel was stained with Coomassie brilliant blue. The purified 
enzyme was chromatoyraphed ona TSK G3000SW,, column (G x 300 
mm) equilibrated with 20 mM phosphate buBer (0. I M NaCI, pH 7.0). 
The purilicd enzyme was chromatopraphcd onan RP-304 column at 
a flow ralr of 1 .O ml/min with a gradient of O-9545 acetonilrile using 
buffer A and buffer 6, and the puriticd subunits were analyzed for the 
N-terminal amino acid sequence. 
3, RESULTS AND DISCUSSION 
We first examined the cleavage sites of AP33 in an 
extract of rat brain. The brain homogenate of B-week- 
old rats was fractionated by gel filtration on two Se- 
phadex G-l 50 colums (Fig. 1A). Most of t!le AP33 frag- 
mentation activity was eluted in the high-molecular- 
mass fraction (M,>lOO kDa). To identify the cleavage 
sites, AP33 was incubated with the high-molecular-mass 
fraction, and the resulting fragments were purified by 
reverse-phase HPLC (Fig, 1 B). The sequencing of these 
fragments revealed that the cleavage sites were at the 
Argl”-His’“, Gln15-Lys , I6 Val’*-Phe’” and Phe’9-Phe’o 
bonds of the/I-AP sequence, The main cleavage site was 
at the Gl~~‘~-Lys” bond, This finding is consistent with 
the known APP processing site, i.e. Gln’s-Lys’6 or 
Lys“-Leu” bond, which was confirmed by direct pro- 
tein structural analysis of the secreted fragment of na- 
tive human APP in transfected cells [9]. There were 
some fragments cleaved at a middle site between Arg’” 
and Phe’” of the ,&AP sequence, but no fragment due 
to cleavage at the site of the Met-l--Asp1 bond. This 
result suggests the presence of APP-processing en- 
zyme(s), but no activeS-AP-releasing enzyme in the rat 
brain, 
We purified the APP-processing enzyme, which 
cleaved P-AP at the site of the Gln15-Lys16 bond, from 
about 130 rat brains. The active fractions from two 
Sephadex G-l 50 columns were fractionated on a ben- 
zamidine-Sepharose 6B column (Fig. 2A). The main 
active fraction was further purified by anion-exchange 
chromatography on a TSK DEAE-SPW column and 
rechromatographed 011 ii-115 same column (Fig. 2B). The 
enzyme was eluted as single symmetrical peak. 
The purity of the finally purified enzyme was exam- 
ined by native PAGE. As is evident from Fig. 2C, the 
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Fig. I, Separalion of APP-PrOceSSitIg enzyme from the extract of ral 
brain by gel filtration on Sephadex G-150 (A). Separation and idcnti- 
fcation of the frsgmcnts of AP33 cleaved by rat brain extract (B), 
AP33 was incubated with the partially purified active fractions 
(M,>lOO kDa) on Sephadex G-150. The resulting fragments were 
separated by reverse-phase HPLC and anulyzed for the amino acid 
sequence. The sequences are shown using the one-letter code. X repre- 
sents an undetermined residue. 
enzyme was apparently purified to homogeneity. The 
enzyme was eluted as single peak coincident with the 
APP-processing activity by gei-fiitration chromatogra- 
phy on a TSK Ci3000SW,, column. The molecular 
mass of the native enzyme was estimated at about 600 
kDa by native PAGE and by gel filtration. The native 
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Fig. 2. Separation of APP-processing enyme by beozamidinc-depha- 
rose at-tinily chromatography (A) and by DEAE-SPW tc%hromatogm- 
phy (B). Native (C) and SDS-PAGE (D) of the purified APP-process- 
ing enzyme. 
enzyme was dissociated into about ten different sub- 
units in the molecular mass range of 22 kDa-32 kDa by 
SDS-PAGE (Fig. 2D). Thirteen subunits of the enzyme 
were partially separated by reverse-phase HPLC on an 
RF-304 column (data not shown). The N-terminal se- 
quence of one of the subunits (25 kDa) was identified 
as X-Gln-Asn-Pro-Met-X-Thr-Gly-Thr-Ser, which is 
identical to that of the B-subunit of human macropain 
[123. Based on these results, we concluded that the APP- 
processing enzyme was a macropain-like proteinase 
1131. 
statin (data not shown). Analysis of the substrate spec- 
ificity using methylcoumarinamide-labeled synthetic 
peptides revealed that the enzyme cleaved the C-termi- 
nal bonds of Tyr. Trp and Arg residues (data not 
shown). These findings suggest that the APP-processing 
enzyme is a multicatalytic neutral proteinase. Our re- 
sults show that this multicatalytic proteinase correctly 
cleaves the GlnlS-Lys I(1 bond of p-AP, but does not 
further degrade@-AP (Fig. 3A), and thus this is a candi- 
date for the authentic APP-processing enzyme. 
When AP33 (1 pg) was incubated with this purified To examine the effects of metal ions on the APP- 
enzyme (0.26 pug) for 1 h, 37°C and pH 2-10, the max- processing activity, we compared the fragmentation of 
imum APB-processing activity was genetated zt pH 65 
8. The APP-processing activity was inhibited at a final 
AP33 (1 ,ug) by the purified enzyme (0.26 &g) in the 
presence of 25 mM Ca2+, M$+, Mn?’ and Zn2’ for 1 h 
concentration of 100 pg/mI by leupeptin, chymostatin incubation. Zn2+ inhibited the enzyme. Ca” altered the 
and antipain, but not by E-64, phosphoramidon or pep- AP33 fragmentation protile by the enzyme, producing 
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Fig. 3. Effects of Ca’* on APP-processing activity. AP33 (1~6) was 
incubated with 2 ~1(0.26& of the purilkd enzyme in 40 ~11 of 0.1 M 
phosphate buffer, p# 7.0 in the absence (A) or presence (B) oF25 mM 
Ca” for I h at 37°C. AP33 (50 fig) was incubated with 1.3 ~8 of the 
purified enzyme in 200 ,ul of assay buffer containing 0.6 mM Ca2+ for 
3 h at 37% (C). The resulting peptidc fragmz~~tnts werepurified and 
analyzed for the amino acid sequence. 
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new peptide fragments (Fig. 3B). We examined the frag- 
mentation of AP33 (50 ,~g) by the purified enzyme (1.3 
pug) in the presence of 0.6 mM Ca” for 3 h incubation 
to confirm the cleavage site (Fig. 3C). The sequences of 
the fragments howed that the APP-processing enzyme 
cleaved the peptide only at the GInI’-Lys16 bond, but 
also cleaved the peptide at the Met-‘-Asp’ and Asp’- 
Ala’ bonds, the N terminus of /3-AP, in the presence of 
Ca?‘. Much to our surprise, wi- found that the purified 
enzyme generated the extmcellular fragment of /?-AP, 
i.e. peak 7 in Fig. 3C. This finding suggests that the 
APP-processing enzyme changes to a p-AP-releasing 
enzyme. 
We have thus identified a macropain-like multicata- 
lytic proteinase (also known as proteasome [14] and 
ingensin [15]) as a candidate for the APP-processing 
enzyme which cleaves at the Gin”-Lys’” bond offl-AP. 
It is very important to note that the purified APP-proc- 
essing enzyme also cleaved the Met-‘-Asp’ and Asp’- 
Ala? bonds of p-AP to release the extracellular domain 
of b-AP in the presence of Ca”‘. These findings lead to 
the new hypothesis that the generation of,&AP in AD 
may be due to the functional change in the multicata- 
lytic proteinase. We have not confirmed whether the 
multicatalytic proteinase acts on the intact APP. How- 
ever, the I I .8 kDa and 11.4 kDa C-terminal APP deriv- 
atives containing the entire ,&AP at or near their N- 
terminus are shown to be present in human cerebral 
cortex [ 161. These derivatives could be cleaved by the 
multicatalytic proteinase. Excessive rises in intracellular 
calcium have been implicated in AD [ 17,183. The abnor- 
malities of cell membrane phospholipid metabolism 
have also been shown in AD brain [19]. The accumula- 
tion of glycerophosphocholine suggests the increased 
activity of the deacylation pathway of phosphati- 
dylcholine, which results in the increase of fatty acid. 
Fatty acids are known to enhance the chymotrypsin-like 
activity of the multicatalytic proteinase [151. Taken to- 
gether with our findings, there is a possibility that an 
abnormality of the system regulating the multicatalytic 
proteinase may be involved in AD. 
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